-
Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page
Part time EPBU CSO gone..
- Thread starter Anonymous
- Start date
-
- Tags
- None
Can you share when it is over? It was supposed to be renewed until june2016
Why is it funded through 2019 on five year plan?
Where are you getting your information? Love to see these puts go
I was just wondering if they would give Zetia/Vytorin over to the EPBU soon. Guess this thread answers my ?.
Has the EPBU been told yet? We were told their contract was going through part of 2016. Why would they end it early. And where are you getting your facts?
Move along folks. Just the usual uninformed rumor mill.....business as usual
Ran into the EPBU rep yesterday, she didn't say anything about layoffs, but did say that they and the DF Respiratory reps will have to send back all their Dulera. They were told because of a packaging update. Sounds like Liptruzet all over again. What gives?
It was originally supposed to end in June 2016. Did they change the date?
My EPBU rep has all dulera and asmanex on hold for packaging reasons and no nasonex?? Flonase otc and new combo therapy out from Teva it doesn't look good for this contract...
So. You are saying Mother will throw away the revenue from those products and fold the cheapest sales force in the history of pharma.
Think different.
Keep EPBU, expand them, and give them diabetes product responsibility and phase them into the the primary sales force after a year or two. If that doesn't resonate, ask the old resp reps if they saw that coming.
It amazes me at the stupidity. As time passes more products fall into the ESTABLISHED basket. That puts us into the expendable basket.